FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159504397> ?p ?o ?g. }

• W3159504397 endingPage "1686" @default.
• W3159504397 startingPage "1677" @default.
• W3159504397 abstract "Personalized treatment for patients with membranous nephropathy requires accurate prediction of the disease course at an early stage. In this study, we evaluated the value of baseline anti-phospholipase A2 receptor (PLA2R1) antibody titer as a prognostic biomarker in patients with PLA2R1-associated membranous nephropathy.In this cohort study, we included 168 patients (118 men, 50 women) referred to our nephrology center between February 1995 and November 2016. Mean age was 52 ± 13 years. There were 156 patients with new-onset disease and 12 patients with a relapse (n = 10) or recent use of immunosuppressive therapy (n = 2). We measured anti-PLA2R1 titer at baseline and analyzed progression to severe disease (30% increase of serum creatinine or start of immunosuppressive therapy) as a primary study endpoint over 60 months.There was a clear association between anti-PLA2R1 antibody titer and severity of the nephrotic syndrome. In univariate analysis, anti-PLA2R1 antibody titer was also associated with disease progression. However, in Cox proportional hazard models that included proteinuria and serum creatinine, anti-PLA2R1 antibody titer was no longer associated with clinical outcome. Results were similar when limiting the analysis to the patients with new-onset disease.Our study questions the relevance of single measurement of anti-PLA2R1 antibodies at baseline as a prognostic biomarker in membranous nephropathy. Future studies are needed to determine the possible role of sequential measurements of anti-PLA2R1 antibodies as a prognostic biomarker of disease progression." @default.
• W3159504397 created "2021-05-10" @default.
• W3159504397 creator A5001178420 @default.
• W3159504397 creator A5011063082 @default.
• W3159504397 creator A5015051666 @default.
• W3159504397 creator A5060591354 @default.
• W3159504397 creator A5082862523 @default.
• W3159504397 creator A5082931018 @default.
• W3159504397 creator A5084032457 @default.
• W3159504397 date "2021-06-01" @default.
• W3159504397 modified "2023-10-18" @default.
• W3159504397 title "Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy" @default.
• W3159504397 cites W2034759249 @default.
• W3159504397 cites W2037144516 @default.
• W3159504397 cites W2038390766 @default.
• W3159504397 cites W2039693612 @default.
• W3159504397 cites W2097148864 @default.
• W3159504397 cites W2099390796 @default.
• W3159504397 cites W2105012343 @default.
• W3159504397 cites W2108432978 @default.
• W3159504397 cites W2116177442 @default.
• W3159504397 cites W2117533352 @default.
• W3159504397 cites W2125503275 @default.
• W3159504397 cites W2127127482 @default.
• W3159504397 cites W2128089274 @default.
• W3159504397 cites W2146086822 @default.
• W3159504397 cites W2166822765 @default.
• W3159504397 cites W2195718607 @default.
• W3159504397 cites W2232005825 @default.
• W3159504397 cites W2470335436 @default.
• W3159504397 cites W2591526768 @default.
• W3159504397 cites W2767487300 @default.
• W3159504397 cites W2785817529 @default.
• W3159504397 cites W2792089093 @default.
• W3159504397 cites W2910019464 @default.
• W3159504397 cites W2972692227 @default.
• W3159504397 cites W2994706881 @default.
• W3159504397 doi "https://doi.org/10.1016/j.ekir.2021.04.002" @default.
• W3159504397 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8207302" @default.
• W3159504397 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34169209" @default.
• W3159504397 hasPublicationYear "2021" @default.
• W3159504397 type Work @default.
• W3159504397 sameAs 3159504397 @default.
• W3159504397 citedByCount "16" @default.
• W3159504397 countsByYear W31595043972021 @default.
• W3159504397 countsByYear W31595043972022 @default.
• W3159504397 countsByYear W31595043972023 @default.
• W3159504397 crossrefType "journal-article" @default.
• W3159504397 hasAuthorship W3159504397A5001178420 @default.
• W3159504397 hasAuthorship W3159504397A5011063082 @default.
• W3159504397 hasAuthorship W3159504397A5015051666 @default.
• W3159504397 hasAuthorship W3159504397A5060591354 @default.
• W3159504397 hasAuthorship W3159504397A5082862523 @default.
• W3159504397 hasAuthorship W3159504397A5082931018 @default.
• W3159504397 hasAuthorship W3159504397A5084032457 @default.
• W3159504397 hasBestOaLocation W31595043971 @default.
• W3159504397 hasConcept C126322002 @default.
• W3159504397 hasConcept C203014093 @default.
• W3159504397 hasConcept C207103383 @default.
• W3159504397 hasConcept C2775946357 @default.
• W3159504397 hasConcept C2779561371 @default.
• W3159504397 hasConcept C2780091579 @default.
• W3159504397 hasConcept C2780306776 @default.
• W3159504397 hasConcept C2781197716 @default.
• W3159504397 hasConcept C44249647 @default.
• W3159504397 hasConcept C50382708 @default.
• W3159504397 hasConcept C55493867 @default.
• W3159504397 hasConcept C71924100 @default.
• W3159504397 hasConcept C86803240 @default.
• W3159504397 hasConcept C90924648 @default.
• W3159504397 hasConceptScore W3159504397C126322002 @default.
• W3159504397 hasConceptScore W3159504397C203014093 @default.
• W3159504397 hasConceptScore W3159504397C207103383 @default.
• W3159504397 hasConceptScore W3159504397C2775946357 @default.
• W3159504397 hasConceptScore W3159504397C2779561371 @default.
• W3159504397 hasConceptScore W3159504397C2780091579 @default.
• W3159504397 hasConceptScore W3159504397C2780306776 @default.
• W3159504397 hasConceptScore W3159504397C2781197716 @default.
• W3159504397 hasConceptScore W3159504397C44249647 @default.
• W3159504397 hasConceptScore W3159504397C50382708 @default.
• W3159504397 hasConceptScore W3159504397C55493867 @default.
• W3159504397 hasConceptScore W3159504397C71924100 @default.
• W3159504397 hasConceptScore W3159504397C86803240 @default.
• W3159504397 hasConceptScore W3159504397C90924648 @default.
• W3159504397 hasIssue "6" @default.
• W3159504397 hasLocation W31595043971 @default.
• W3159504397 hasLocation W31595043972 @default.
• W3159504397 hasLocation W31595043973 @default.
• W3159504397 hasLocation W31595043974 @default.
• W3159504397 hasLocation W31595043975 @default.
• W3159504397 hasLocation W31595043976 @default.
• W3159504397 hasLocation W31595043977 @default.
• W3159504397 hasLocation W31595043978 @default.
• W3159504397 hasOpenAccess W3159504397 @default.
• W3159504397 hasPrimaryLocation W31595043971 @default.
• W3159504397 hasRelatedWork W2025805266 @default.
• W3159504397 hasRelatedWork W2104709702 @default.
• W3159504397 hasRelatedWork W2122079536 @default.

• next